Long‑Term Follow‑Up of Adjuvant Imatinib for Localized Gastrointestinal Stromal Tumors
Adjuvant imatinib improves relapse‑free survival in patients with localized gastrointestinal stromal tumor, particularly in the high‑risk subgroup.
These results support the continued use of 3‑year adjuvant imatinib as standard of care for high‑risk GIST patients, emphasizing the importance of patient selection and treatment duration.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)